AAA Screening in Men Over 65 Reduces Mortality

screening abdominal aortic aneurysmSystematic screening for abdominal aortic aneurysm (AAA) targeting all men over 65 years old (not just those presenting risk factors) was associated with a drop in the mortality rate specific for this disease, according to the Swedish Nationwide Screening Program.

 

While 667 men were examined for AAA, the number of patients who required treatment to prevent premature death due to aneurysm rupture was merely 1.5.

 

Such amazing treatment efficacy justifies screening despite the relatively low prevalence of this disease.

 

Randomized studies showed that screening through ultrasound followed by preventive surgery can reduce associated mortality in selected populations, but such a selection differs by location. This is, precisely, the novelty in this study: no selection was made; all men over 65 years old were studied.

 

In this registry, of 302,957 men who received an invitation to be screened, 84% finally accepted, a very high percentage.

 

AAA was detected in 1.5% of men, 29% of which underwent preventive surgery over a mean follow-up of 4.5 years.

 

Mortality at 30 days was significantly lower for endovascular treatment compared to open surgery.

 

Endovascular treatment: 0.3%

Open surgery:  1.3%

(p <0.001)

 

There was a significant reduction in mortality (4%) per year of screening (p = 0.02).

 

From 2000 (before the introduction of screening) to 2014, associated mortality dropped from 74 to 45 patients every 100,000 subjects.

 

Conclusion

Systematic screening for abdominal aortic aneurysm in men over 65 years old is highly cost-effective and reduces mortality associated to aneurysm rupture.

 

Original title: Outcome of the Swedish nationwide abdominal aortic aneurysm screening program.

Reference: Wanhainen A et al. Circulation 2016; Epub ahead of print.

 

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...